MCID: ANG015
MIFTS: 55

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 74 54 6 43 15 17 71
Angioneurotic Oedema 12 32
Quincke's Edema 12 74
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
MeSH 43 D000799
NCIt 49 C112175
SNOMED-CT 67 41291007 82966003
ICD10 32 T78.3
UMLS 71 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as angioneurotic oedema, is related to acquired angioedema and hereditary angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Enalapril and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and tongue, and related phenotype is behavior/neurological.

Wikipedia : 74 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 523, show less)
# Related Disease Score Top Affiliating Genes
1 acquired angioedema 34.8 SERPING1 C1S
2 hereditary angioedema 34.4 XPNPEP2 SERPING1 KNG1 KLKB1 F12 C1S
3 non-histaminic angioedema 34.4 SYTL2 F12
4 c1 inhibitor deficiency 33.6 SERPING1 KNG1 KLKB1 F12 C1S BDKRB2
5 hydrops, lactic acidosis, and sideroblastic anemia 31.5 SERPING1 PTGS2 PTGS1 KNG1 C1S
6 physical urticaria 31.2 SERPING1 KNG1 HRH1
7 cholinergic urticaria 31.1 SERPING1 HRH1
8 allergic hypersensitivity disease 31.0 KNG1 IL5 IGHE HRH1
9 food allergy 30.9 IL5 IGHE HRH1
10 allergic urticaria 30.9 SERPING1 KNG1
11 drug allergy 30.9 IL5 IGHE ACE
12 urticaria 30.6 SERPING1 PTGS2 PTGS1 LTC4S IL5 IGHE
13 end stage renal failure 30.5 PTGS2 BDKRB2 AGTR2 ACE
14 allergic rhinitis 30.4 KNG1 IL5 IGHE HRH1
15 rhinitis 30.3 PTGS1 KNG1 IL5 IGHE HRH1
16 proteasome-associated autoinflammatory syndrome 1 30.2 PTGS2 PTGS1 IL5
17 conjunctivitis 30.2 IL5 IGHE HRH1
18 gastroesophageal reflux 30.2 PTGS2 PTGS1 IL5
19 dermatitis, atopic 29.8 KNG1 IL5 IGHE HRH1 DPP4
20 cardiovascular system disease 29.6 PTGS2 PTGS1 MME KNG1 AGTR2 ACE
21 myocardial infarction 29.2 SERPING1 PTGS2 PTGS1 MME KNG1 DPP4
22 asthma 29.2 PTGS1 MME LTC4S KNG1 IL5 IGHE
23 hypertension, essential 29.0 PTGS2 PTGS1 MME KNG1 KLKB1 F12
24 angioedema, hereditary, type i 12.8
25 angioedema, hereditary, type iii 12.8
26 angioedema induced by ace inhibitors 12.8
27 episodic angioedema with eosinophilia 12.6
28 hereditary angioedema with normal c1inh 12.3
29 hereditary angioedema with c1inh deficiency 12.2
30 acquired angioedema type 1 12.2
31 acquired angioedema type 2 12.2
32 vibratory urticaria 12.2
33 plg-related hereditary angioedema with normal c1inh 12.1
34 angpt1-related hereditary angioedema with normal c1inh 12.1
35 acquired angioedema with c1inh deficiency 12.1
36 complement component 4, partial deficiency of 11.7
37 cold urticaria 11.5
38 loiasis 11.5
39 carboxypeptidase n deficiency 11.3
40 netherton syndrome 11.2
41 hypereosinophilic syndrome 10.6
42 melkersson-rosenthal syndrome 10.6 SERPING1 ACE
43 fissured tongue 10.5 SERPING1 ACE
44 familial vesicoureteral reflux 10.5 AGTR2 ACE
45 malignant essential hypertension 10.5 KNG1 KLKB1 ACE
46 exanthem 10.5
47 pyruvate kinase deficiency of red cells 10.5 KNG1 KLKB1 BDKRB2
48 cefuroxime allergy 10.5 PTGS2 IL5
49 aspirin resistance 10.5 PTGS2 PTGS1
50 diffuse scleroderma 10.5 KNG1 ACE
51 posterior urethral valves 10.5 AGTR2 ACE
52 granulomatous angiitis 10.5 IL5 ACE
53 idiopathic nephrotic syndrome 10.5 IGHE ACE
54 myocardial stunning 10.4 KNG1 AGTR2 ACE
55 autoimmune disease 10.4
56 vasculitis 10.4
57 lupus erythematosus 10.4
58 kidney papillary necrosis 10.4 PTGS2 PTGS1 ACE
59 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.4 PTGS2 PTGS1
60 bursitis 10.4 PTGS2 KNG1
61 trypanosomiasis 10.4 KNG1 BDKRB2 ACE
62 systemic lupus erythematosus 10.4
63 diarrhea 10.4
64 active peptic ulcer disease 10.4 PTGS2 PTGS1
65 congenital nonspherocytic hemolytic anemia 10.4 KNG1 KLKB1
66 renal hypertension 10.4 KNG1 KLKB1 AGTR2 ACE
67 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
68 atopic keratoconjunctivitis 10.4 IL5 IGHE
69 toxic oil syndrome 10.3 IL5 IGHE
70 lymphoproliferative syndrome 10.3
71 cough variant asthma 10.3 IL5 IGHE ACE
72 uveoparotid fever 10.3 SERPING1 ACE
73 dysphagia 10.3
74 vernal keratoconjunctivitis 10.3 IL5 IGHE
75 ige responsiveness, atopic 10.3
76 lymphoma 10.3
77 congestive heart failure 10.3
78 chronic conjunctivitis 10.3 IL5 IGHE HRH1
79 allergic conjunctivitis 10.2 IL5 IGHE HRH1
80 neurodermatitis 10.2
81 stroke, ischemic 10.2
82 contact dermatitis 10.2
83 cerebrovascular disease 10.2
84 toxocariasis 10.2 IL5 IGHE
85 chronic cystitis 10.2 PTGS2 PTGS1
86 intrinsic asthma 10.2 IL5 IGHE
87 acute pancreatitis 10.2
88 glomerulonephritis 10.2
89 dermatitis 10.2
90 pancreatitis 10.2
91 thyroiditis 10.2
92 macroglossia 10.2
93 capillary leak syndrome 10.2
94 allergic contact dermatitis 10.2
95 disseminated intravascular coagulation 10.1
96 intussusception 10.1
97 cellulitis 10.1
98 crohn's disease 10.1
99 48,xyyy 10.1
100 hashimoto thyroiditis 10.1
101 lymphoma, hodgkin, classic 10.1
102 lymphoma, non-hodgkin, familial 10.1
103 hypothyroidism 10.1
104 mastocytosis 10.1
105 alopecia 10.1
106 cytokine deficiency 10.1
107 mastocytosis, cutaneous 10.1
108 osteomyelitis 10.1
109 pleurisy 10.1
110 intracranial aneurysm 10.1
111 visual epilepsy 10.1
112 extrinsic allergic alveolitis 10.1
113 myoclonus 10.1
114 seizure disorder 10.1
115 helicobacter pylori infection 10.1
116 marginal zone b-cell lymphoma 10.1
117 cheilitis 10.1
118 gastroenteritis 10.1
119 ischemia 10.1
120 skin disease 10.1
121 kidney disease 10.1
122 ileus 10.1
123 acute mountain sickness 10.1 BDKRB2 ACE
124 dermatomyositis 10.0
125 childhood type dermatomyositis 10.0
126 pemphigoid gestationis 10.0
127 epilepsy 10.0
128 fibrillary glomerulonephritis 10.0
129 neurofibromatosis, type ii 10.0
130 leukemia, chronic lymphocytic 10.0
131 thrombophilia due to thrombin defect 10.0
132 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
133 microvascular complications of diabetes 3 10.0
134 microvascular complications of diabetes 4 10.0
135 microvascular complications of diabetes 6 10.0
136 microvascular complications of diabetes 7 10.0
137 splenic marginal zone lymphoma 10.0
138 cardiac arrest 10.0
139 lymphocytic leukemia 10.0
140 respiratory failure 10.0
141 esophagitis 10.0
142 graves' disease 10.0
143 vascular disease 10.0
144 dystonia 10.0
145 connective tissue disease 10.0
146 appendicitis 10.0
147 arthritis 10.0
148 fasciitis 10.0
149 47,xyy 10.0
150 paragonimiasis 10.0 IL5 IGHE
151 coproporphyria, hereditary 10.0
152 cyclic neutropenia 10.0
153 vitiligo-associated multiple autoimmune disease susceptibility 6 10.0
154 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
155 nasopharyngeal carcinoma 10.0
156 severe cutaneous adverse reaction 10.0
157 hereditary lymphedema 10.0
158 hemorrhagic cystitis 10.0
159 charcot-marie-tooth disease 10.0
160 tooth disease 10.0
161 erysipelas 10.0
162 neutropenia 10.0
163 leukemia 10.0
164 leiomyoma 10.0
165 telangiectasis 10.0
166 opisthorchiasis 10.0
167 renal tubular acidosis 10.0
168 cystitis 10.0
169 angiodysplasia 10.0
170 ludwig's angina 10.0
171 proliferative glomerulonephritis 10.0
172 lymphopenia 10.0
173 gastrointestinal system disease 10.0
174 pityriasis versicolor 10.0
175 amyloidosis 10.0
176 accessory pancreas 10.0
177 leukoplakia 10.0
178 spondylarthropathy 10.0
179 stevens-johnson syndrome/toxic epidermal necrolysis 10.0
180 rare systemic disease 10.0
181 periodic paralysis 10.0
182 erythema multiforme major 10.0
183 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.0
184 thyroid carcinoma 10.0
185 familial mediterranean fever 10.0
186 myeloma, multiple 10.0
187 anxiety 10.0
188 erythema multiforme 10.0
189 inflammatory bowel disease 10.0
190 immunoglobulin alpha deficiency 10.0
191 hepatitis a 10.0
192 adult-onset still's disease 10.0
193 panniculitis 10.0
194 rheumatic disease 10.0
195 pneumothorax 10.0
196 hepatitis c 10.0
197 hepatitis b 10.0
198 hepatitis 10.0
199 myopathy 10.0
200 adenoma 10.0
201 b-cell lymphoma 10.0
202 hyperthyroidism 10.0
203 peritonitis 10.0
204 pulmonary embolism 10.0
205 hemophilia 10.0
206 carcinoid syndrome 10.0
207 hypocomplementemic urticarial vasculitis 10.0
208 pik3ca-related overgrowth syndrome 10.0
209 pfeiffer syndrome 9.9
210 spondyloarthropathy 1 9.9
211 atherosclerosis susceptibility 9.9
212 hepatocellular carcinoma 9.9
213 renal cell carcinoma, nonpapillary 9.9
214 rheumatoid arthritis 9.9
215 thrombophilia due to activated protein c resistance 9.9
216 anemia, autoimmune hemolytic 9.9
217 celiac disease 1 9.9
218 complement component 2 deficiency 9.9
219 eosinophilic fasciitis 9.9
220 immune deficiency disease 9.9
221 myelofibrosis 9.9
222 myxedema 9.9
223 periodontitis, chronic 9.9
224 psoriatic arthritis 9.9
225 hypereosinophilic syndrome, idiopathic 9.9
226 intraocular pressure quantitative trait locus 9.9
227 membranous nephropathy 9.9
228 deficiency anemia 9.9
229 anaplastic large cell lymphoma 9.9
230 lymphoplasmacytic lymphoma 9.9
231 peripheral t-cell lymphoma 9.9
232 follicular lymphoma 9.9
233 aphasia 9.9
234 fish allergy 9.9
235 endometrial hyperplasia 9.9
236 parotitis 9.9
237 prostatic hypertrophy 9.9
238 hypoparathyroidism 9.9
239 heart disease 9.9
240 hypertensive heart disease 9.9
241 nephrotic syndrome 9.9
242 inflammatory spondylopathy 9.9
243 goiter 9.9
244 common variable immunodeficiency 9.9
245 pancytopenia 9.9
246 guillain-barre syndrome 9.9
247 gout 9.9
248 facial paralysis 9.9
249 toxic shock syndrome 9.9
250 thrombocytopenia 9.9
251 melanoma 9.9
252 cholecystitis 9.9
253 rectum cancer 9.9
254 enthesopathy 9.9
255 membranoproliferative glomerulonephritis 9.9
256 antiphospholipid syndrome 9.9
257 acute kidney failure 9.9
258 purpura 9.9
259 blepharochalasis 9.9
260 brain edema 9.9
261 hemolytic anemia 9.9
262 complement deficiency 9.9
263 spondylitis 9.9
264 compartment syndrome 9.9
265 monoclonal gammopathy of uncertain significance 9.9
266 peptic ulcer disease 9.9
267 myocarditis 9.9
268 periodontitis 9.9
269 collagen disease 9.9
270 herpes simplex 9.9
271 macroglobulinemia 9.9
272 necrotizing fasciitis 9.9
273 stomatitis 9.9
274 irritable bowel syndrome 9.9
275 alopecia areata 9.9
276 acquired hemophilia 9.9
277 macrophage activation syndrome 9.9
278 papular urticaria 9.9
279 splenomegaly 9.9
280 raynaud phenomenon 9.9
281 depression 9.9
282 chronic pain 9.9
283 headache 9.9
284 recurrent acute pancreatitis 9.9
285 discoid lupus erythematosus 9.9
286 ulcerative colitis 9.8
287 hypoglycemia 9.8
288 atrial standstill 1 9.7
289 blepharochalasis and double lip 9.7
290 burkitt lymphoma 9.7
291 colorectal cancer 9.7
292 cardiac arrhythmia 9.7
293 carpal tunnel syndrome 9.7
294 cheilitis glandularis 9.7
295 major affective disorder 1 9.7
296 immunoglobulin a deficiency 1 9.7
297 hair whorl 9.7
298 periodic fever, familial, autosomal dominant 9.7
299 hypercholesterolemia, familial, 1 9.7
300 lipomatosis, multiple 9.7
301 migraine with or without aura 1 9.7
302 myositis 9.7
303 osteoporosis 9.7
304 pancreatitis, hereditary 9.7
305 pemphigus vulgaris, familial 9.7
306 pernicious anemia 9.7
307 protoporphyria, erythropoietic, 1 9.7
308 pulmonary hypertension, primary, 1 9.7
309 raynaud disease 9.7
310 scleroderma, familial progressive 9.7
311 small cell cancer of the lung 9.7
312 temporal arteritis 9.7
313 thrombocytopenic purpura, autoimmune 9.7
314 urticaria, aquagenic 9.7
315 varicose veins 9.7
316 alopecia universalis congenita 9.7
317 chiari malformation type ii 9.7
318 lung cancer 9.7
319 enterocolitis 9.7
320 leprosy 3 9.7
321 myasthenia gravis 9.7
322 ocular motor apraxia 9.7
323 polycythemia vera 9.7
324 allan-herndon-dudley syndrome 9.7
325 fabry disease 9.7
326 arts syndrome 9.7
327 muscular dystrophy, duchenne type 9.7
328 androgen insensitivity, partial 9.7
329 gonadoblastoma 9.7
330 ataxia and polyneuropathy, adult-onset 9.7
331 kearns-sayre syndrome 9.7
332 gallbladder disease 1 9.7
333 yemenite deaf-blind hypopigmentation syndrome 9.7
334 body mass index quantitative trait locus 1 9.7
335 gastrointestinal stromal tumor 9.7
336 anorexia nervosa 9.7
337 pulmonary disease, chronic obstructive 9.7
338 endometrial cancer 9.7
339 major depressive disorder 9.7
340 granulomatosis with polyangiitis 9.7
341 hepatitis c virus 9.7
342 bone mineral density quantitative trait locus 8 9.7
343 major affective disorder 8 9.7
344 major affective disorder 9 9.7
345 antithrombin iii deficiency 9.7
346 bone mineral density quantitative trait locus 15 9.7
347 alpha-1-antitrypsin deficiency 9.7
348 mannose-binding lectin deficiency 9.7
349 leptin deficiency or dysfunction 9.7
350 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
351 autoimmune lymphoproliferative syndrome, type v 9.7
352 hyperlipoproteinemia, type iii 9.7
353 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
354 chlamydia pneumonia 9.7
355 cutaneous lupus erythematosus 9.7
356 small cell carcinoma 9.7
357 mantle cell lymphoma 9.7
358 metabolic acidosis 9.7
359 oromandibular dystonia 9.7
360 sleep apnea 9.7
361 alexithymia 9.7
362 pain agnosia 9.7
363 colitis 9.7
364 crohn's colitis 9.7
365 atrial fibrillation 9.7
366 inguinal hernia 9.7
367 penicillin allergy 9.7
368 purpura fulminans 9.7
369 thrombosis 9.7
370 angioimmunoblastic t-cell lymphoma 9.7
371 pleomorphic lipoma 9.7
372 ehrlichiosis 9.7
373 mumps 9.7
374 sialadenitis 9.7
375 siderosis 9.7
376 bacterial infectious disease 9.7
377 tonsillitis 9.7
378 common cold 9.7
379 nasopharyngitis 9.7
380 pre-eclampsia 9.7
381 filariasis 9.7
382 chlamydia 9.7
383 adult respiratory distress syndrome 9.7
384 pulmonary edema 9.7
385 horner's syndrome 9.7
386 polycystic ovary syndrome 9.7
387 hyperandrogenism 9.7
388 iron deficiency anemia 9.7
389 coronary artery anomaly 9.7
390 aseptic meningitis 9.7
391 trichuriasis 9.7
392 hemolytic-uremic syndrome 9.7
393 miller fisher syndrome 9.7
394 dilated cardiomyopathy 9.7
395 ehlers-danlos syndrome 9.7
396 cholestasis 9.7
397 eclampsia 9.7
398 dental fluorosis 9.7
399 amenorrhea 9.7
400 peptic esophagitis 9.7
401 primary angle-closure glaucoma 9.7
402 bacteriuria 9.7
403 papilledema 9.7
404 echinococcosis 9.7
405 nodular nonsuppurative panniculitis 9.7
406 renovascular hypertension 9.7
407 mental depression 9.7
408 lymphadenitis 9.7
409 duodenal ulcer 9.7
410 viral hepatitis 9.7
411 hypogonadism 9.7
412 exostosis 9.7
413 acute maxillary sinusitis 9.7
414 maxillary sinusitis 9.7
415 focal epilepsy 9.7
416 transient cerebral ischemia 9.7
417 pharyngitis 9.7
418 colon adenocarcinoma 9.7
419 iron metabolism disease 9.7
420 macrocytic anemia 9.7
421 protein s deficiency 9.7
422 thrombophilia 9.7
423 opiate dependence 9.7
424 agammaglobulinemia 9.7
425 phimosis 9.7
426 cryoglobulinemia 9.7
427 periarthritis 9.7
428 iga glomerulonephritis 9.7
429 adenocarcinoma 9.7
430 churg-strauss syndrome 9.7
431 cystic lymphangioma 9.7
432 lipid metabolism disorder 9.7
433 bipolar disorder 9.7
434 mood disorder 9.7
435 carotid artery thrombosis 9.7
436 mast cell neoplasm 9.7
437 extramedullary plasmacytoma 9.7
438 plasmacytoma 9.7
439 intestinal pseudo-obstruction 9.7
440 gastritis 9.7
441 eosinophilic gastroenteritis 9.7
442 liver disease 9.7
443 systemic scleroderma 9.7
444 tinea favosa 9.7
445 milk allergy 9.7
446 folliculitis 9.7
447 macular retinal edema 9.7
448 clear cell renal cell carcinoma 9.7
449 extracutaneous mastocytoma 9.7
450 elephantiasis 9.7
451 thyroid gland disease 9.7
452 aortitis 9.7
453 paraphimosis 9.7
454 schizoaffective disorder 9.7
455 peripheral nervous system disease 9.7
456 bronchitis 9.7
457 viral encephalitis 9.7
458 juvenile rheumatoid arthritis 9.7
459 infiltrating lipoma 9.7
460 dermatographia 9.7
461 hypogonadotropism 9.7
462 diverticulitis 9.7
463 chronic kidney disease 9.7
464 cataract 9.7
465 polycythemia 9.7
466 intestinal obstruction 9.7
467 influenza 9.7
468 chickenpox 9.7
469 eating disorder 9.7
470 neuropathy 9.7
471 chorioretinitis 9.7
472 evans' syndrome 9.7
473 peliosis hepatis 9.7
474 gas gangrene 9.7
475 achalasia 9.7
476 pemphigus 9.7
477 speech disorder 9.7
478 priapism 9.7
479 lymphangitis 9.7
480 carotid artery dissection 9.7
481 exophthalmos 9.7
482 epiglottitis 9.7
483 allergic asthma 9.7
484 intracranial hypertension 9.7
485 fatty liver disease 9.7
486 meningitis 9.7
487 dacryoadenitis 9.7
488 bronchiectasis 9.7
489 encephalitis 9.7
490 tenosynovitis 9.7
491 polyarteritis nodosa 9.7
492 muscular dystrophy 9.7
493 dacryocystitis 9.7
494 eosinophilia-myalgia syndrome 9.7
495 sickle cell disease 9.7
496 autoimmune progesterone dermatitis 9.7
497 broken heart syndrome 9.7
498 central serous chorioretinopathy 9.7
499 chiari malformation 9.7
500 complement component deficiency 9.7
501 congenital extrahepatic portosystemic shunt 9.7
502 cutaneous mastocytoma 9.7
503 granulocytopenia 9.7
504 hansen's disease 9.7
505 idiopathic edema 9.7
506 lymphomatoid granulomatosis 9.7
507 lymphomatous thyroiditis 9.7
508 mallory-weiss syndrome 9.7
509 mast cell activation syndrome 9.7
510 periodontal ehlers-danlos syndrome 9.7
511 scleromyxedema 9.7
512 autonomic dysfunction 9.7
513 hypertonia 9.7
514 syncope 9.7
515 tremor 9.7
516 subacute cutaneous lupus erythematosus 9.7
517 b-cell non-hodgkin lymphoma 9.7
518 progressive muscular dystrophy 9.7
519 acute liver failure 9.7
520 lymphedema 9.7
521 rare surgical neurologic disease 9.7
522 solar urticaria 9.7
523 autoinflammatory syndrome 9.7

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

MGI Mouse Phenotypes related to Angioedema:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.4 ACE AGTR2 BDKRB2 CPN1 HNMT HRH1

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 261, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Methadone Approved Phase 4 76-99-3 4095
6
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
7
Azithromycin Approved Phase 4 83905-01-5 447043 55185
8
Ethanol Approved Phase 4 64-17-5 702
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
11
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
12
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
13
Budesonide Approved Phase 4 51333-22-3 63006 5281004
14
Omalizumab Approved, Investigational Phase 4 242138-07-4
15
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
19
Icatibant Approved, Investigational Phase 4 138614-30-9, 130308-48-4 71364
20
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
21
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
22
Bradykinin Investigational Phase 4 58-82-2 439201
23 Antiviral Agents Phase 4
24 Protective Agents Phase 4
25 Antioxidants Phase 4
26 N-monoacetylcystine Phase 4
27 Narcotics Phase 4
28 Free Radical Scavengers Phase 4
29 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
30 Antidotes Phase 4
31 Antitussive Agents Phase 4
32 Expectorants Phase 4
33 Anti-Ulcer Agents Phase 4
34 Proton Pump Inhibitors Phase 4
35 Antacids Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Hormones Phase 4
38 glucocorticoids Phase 4
39 Hormone Antagonists Phase 4
40 Histamine H1 Antagonists, Non-Sedating Phase 4
41 Cholinergic Agents Phase 4
42 Cholinergic Antagonists Phase 4
43 Autonomic Agents Phase 4
44 Bronchodilator Agents Phase 4
45 Respiratory System Agents Phase 4
46 Anti-Asthmatic Agents Phase 4
47 Rho(D) Immune Globulin Phase 4
48 gamma-Globulins Phase 4
49 Immunoglobulins, Intravenous Phase 4
50 Antibiotics, Antitubercular Phase 4
51 Renal Agents Phase 4
52 Anti-Infective Agents, Urinary Phase 4
53 Cytochrome P-450 Enzyme Inhibitors Phase 4
54 Topoisomerase Inhibitors Phase 4
55 Antitubercular Agents Phase 4
56 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
57 Analgesics, Opioid Phase 4
58 Central Nervous System Depressants Phase 4
59 Anesthetics Phase 4
60 Anesthetics, Local Phase 4
61 HIV Protease Inhibitors Phase 4
62
protease inhibitors Phase 4
63 Vasodilator Agents Phase 4
64 Angiotensin-Converting Enzyme Inhibitors Phase 4
65 Bradykinin Receptor Antagonists Phase 4
66 Kininogens Phase 4
67
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
68
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
69
Iron Approved, Experimental Phase 2, Phase 3 7439-89-6, 15438-31-0 23925 27284
70
Deferoxamine Approved, Investigational Phase 2, Phase 3 70-51-9 2973
71
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
72
Deferasirox Approved, Investigational Phase 2, Phase 3 201530-41-8 5493381
73
tannic acid Approved Phase 3 1401-55-4
74
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
75
Tranexamic Acid Approved Phase 3 1197-18-8 5526
76
Atenolol Approved Phase 3 29122-68-7 2249
77
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
78
Azilsartan medoxomil Approved, Investigational Phase 3 863031-21-4
79
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
80
Levocetirizine Approved Phase 3 130018-77-8 1549000
81
Cortisone Experimental Phase 3 53-06-5 222786
82 Trace Elements Phase 2, Phase 3
83 Micronutrients Phase 2, Phase 3
84 Nutrients Phase 2, Phase 3
85 Albumin-Bound Paclitaxel Phase 3
86 Antimitotic Agents Phase 3
87 Liver Extracts Phase 2, Phase 3
88 Siderophores Phase 2, Phase 3
89 Iron Chelating Agents Phase 2, Phase 3
90 Plasma Kallikrein Phase 3
91 Kallikreins Phase 3
92 Coagulants Phase 3
93 Passionflower Phase 3
94 Fibrinolytic Agents Phase 3
95 Antifibrinolytic Agents Phase 3
96 Hemostatics Phase 3
97 Adrenergic Antagonists Phase 3
98 Adrenergic beta-Antagonists Phase 3
99 Anti-Arrhythmia Agents Phase 2, Phase 3
100 Adrenergic beta-1 Receptor Antagonists Phase 3
101 Antibodies, Monoclonal Phase 3
102 Antibodies Phase 3
103 Immunoglobulins Phase 3
104 Antineoplastic Agents, Hormonal Phase 3
105 Pharmaceutical Solutions Phase 3
106
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
107
Danazol Approved Phase 2 17230-88-5 28417
108
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
109
Racepinephrine Approved Phase 2 329-65-7 838
110
Azathioprine Approved Phase 1, Phase 2 446-86-6 2265
111
Minocycline Approved, Investigational Phase 1, Phase 2 10118-90-8 5281021
112
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
113
Rifaximin Approved, Investigational Phase 2 80621-81-4 6436173 46783403
114
Gemcitabine Approved Phase 2 95058-81-4 60750
115
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
116
Valsartan Approved, Investigational Phase 2 137862-53-4 60846
117
Histamine Approved, Investigational Phase 2 51-45-6 774
118
Cyproheptadine Approved Phase 2 129-03-3 2913
119 Fertility Agents Phase 2
120 Antifungal Agents Phase 1, Phase 2
121 Calcineurin Inhibitors Phase 1, Phase 2
122 Cyclosporins Phase 1, Phase 2
123 Selective Estrogen Receptor Modulators Phase 2
124 Estrogen Antagonists Phase 2
125 Estrogen Receptor Antagonists Phase 2
126 Estrogen Receptor Modulators Phase 2
127 Estrogens Phase 2
128 Epinephryl borate Phase 2
129 Sympathomimetics Phase 2
130 Adrenergic beta-Agonists Phase 2
131 Vasoconstrictor Agents Phase 2
132 Mydriatics Phase 2
133 Antiprotozoal Agents Phase 2
134 Antimony Sodium Gluconate Phase 2
135 Anthelmintics Phase 2
136 Liposomal amphotericin B Phase 2
137 Antiparasitic Agents Phase 2
138 Plasminogen Phase 2
139 Antihypertensive Agents Phase 2
140 Antimetabolites Phase 2
141 Natriuretic Agents Phase 2
142 Natriuretic Peptide, Brain Phase 2
143 Angiotensinogen Phase 2
144 Angiotensin Receptor Antagonists Phase 2
145 Angiotensin II Type 1 Receptor Blockers Phase 2
146 Giapreza Phase 2
147 LCZ 696 Phase 2
148 Gastrointestinal Agents Phase 2
149 Histamine Antagonists Phase 2
150
Histamine Phosphate Phase 2 51-74-1 65513
151 Anti-Allergic Agents Phase 2
152 Histamine H1 Antagonists Phase 2
153 Dermatologic Agents Phase 2
154 Serotonin Agents Phase 2
155 Serotonin Antagonists Phase 2
156 Antipruritics Phase 2
157
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
158
Oxandrolone Approved, Investigational Phase 1 53-39-4 5878
159
Digoxin Approved Phase 1 20830-75-5 30322 2724385
160
Tolbutamide Approved, Investigational Phase 1 64-77-7 5505
161
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
162
Omeprazole Approved, Investigational, Vet_approved Phase 1 73590-58-6 4594